AstraZeneca's Two Lung Cancer Drugs Both Achieve Positive Phase 3 Trial Results
Nashnova编辑部
AstraZeneca's Enhertu and Tagrisso combination each met their primary endpoints in separate Phase III trials, covering different targets and lines of therapy — positive data that, if approved, would widen the company's non-small cell lung cancer franchise.
What did these two trials test?
Both trials target non-small cell lung cancer (NSCLC) — the most common type, roughly 85% of all lung cancers — but at different stages and against different molecular targets.
DESTINY-Lung04 tested whether Enhertu can move from its current second-line approval to first-line use — the very first drug a patient receives after diagnosis.
SAFFRON tested what to do after Tagrisso stops working — whether adding Orpathys to Tagrisso can beat standard chemotherapy in the second-line setting.
This means → the two trials fill in different gaps: one pushes forward to grab the starting slot, the other covers the rear when the frontline drug fails.
Why does Enhertu's first-line data matter?
Enhertu is an ADC — an antibody-drug conjugate that straps a chemotherapy payload onto an antibody, delivering it like a guided missile to cancer cells. It is currently approved only for second-line treatment of HER2-mutant lung cancer.
The trial showed that as a first-line therapy in patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC, Enhertu delivered longer progression-free survival than standard of care.
In plain terms = patients used to have to fail on another drug before they could access Enhertu. This data suggests it could be used from the start, skipping the trial-and-error phase.
This reflects a broader trend: ADC drugs are graduating from backup options to first-choice treatments across oncology.
What pain point does the Tagrisso resistance combo solve?
Tagrisso (osimertinib) is the standard first-line drug for EGFR-mutant lung cancer, but most patients eventually develop resistance. A common mechanism: the tumor develops MET overexpression or amplification.
SAFFRON combined Tagrisso with Orpathys (savolitinib) — a drug that specifically targets MET — and compared it against platinum-based doublet chemotherapy. The combo showed significantly better progression-free survival and overall survival.
This means → for patients whose tumors resist Tagrisso via MET abnormalities, there is now a targeted combination that can replace conventional chemo — with better efficacy and more manageable toxicity.
What does the market watch next?
Positive trial results are data-level validation. Turning them into new approved indications requires regulatory submissions and review by the FDA and other agencies.
Two milestones to track: the filing timeline for Enhertu's first-line indication, and whether the Tagrisso + Orpathys combo wins approval as a standard post-resistance regimen.
In plain terms = a successful trial ≠ an immediate new product — between data and prescription pad sits the regulatory gate.
Content is for reference only, not financial advice.